Botanical and Plant-derived Drugs: Global Markets

Published - Dec 2017| Analyst - Kim Lawson| Code - BIO022H
Botanical and Plant-derived Drugs: Global Markets
Single User License: $4950 Member Price: FREE

Report Highlights

The global market for botanical and plant-derived drugs will grow from $29.4 billion in 2017 to around $39.6 billion by 2022 with a compound annual growth rate (CAGR) of 6.1% for the period of 2017-2022.

 Report Includes 

  • An overview of the botanical drug industry, with the overall plant-derived drug industry as a backdrop and the global market for these drugs going forward
  • Analyses of global market trends, with data from 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022
  • A focus on legal, prescription-required therapeutic medicines sold in the open market; the study does not specifically cover herbals generally sold as dietary supplements (i.e., to promote overall “wellness” rather than to address specific medical conditions or symptoms)
  • Examination of the industry structure, competition, and market drivers
  • Discussion of market size and segmentation, including breakdowns of sales by therapeutic area and geographic area
  • Observations and conclusions regarding the future of the botanical and plant-derived drug industry

Report Scope

This report is an analytical business tool whose primary purpose is to describe the botanical drug industry with the overall plant-derived drug industry as a backdrop and the global market for these drugs going forward.

For the purposes of this report, botanicals are those drugs that are FDA-approved under the botanical drug pathway, while plant-derived drugs are both botanicals as well as other approved drugs that contain a mixture of natural plant-derived and synthetic or semisynthetic substances.

The study’s main focus is on legal, prescription-required therapeutic medicines sold in the open market. The study does not specifically cover herbals generally sold as dietary supplements (i.e., to promote overall “wellness” rather than to address a specific medical condition or symptoms). While there is a substantial market for these products, the medical value of many of these substances has not been demonstrated conclusively.

The study also does not cover the following:

  • Underground or illicit drugs.
  • Home remedies.
  • Tribal medicines.
  • Drugs derived from Archaea, bacteria and fungi (molds and yeasts).
  • Nonmedicinal plant substances, such as laxative cellulose and pectin fiber.
  • Intravenously delivered nutrients of plant origin, such as dextrose.
  • Plant-derived substances serving as pharmaceutical excipients, such as starch, methylcellulose, guar gum, vegetable oils, fatty acids, cocoa butter and candelilla wax.
  • Plant substances serving in cosmetics, toiletries and personal care products.
  • Microbial fermentation products, even those made with culture media incorporating corn steep liquor, starch or other plant-derived nutrients.
  • Marine life.

The format of the study is organized around the following topics:

  • Major types and applications of botanical drugs with plant-derived drugs as their backdrop.
  • Industry structure.
  • Market size and segmentation, including the breakdown of sales by therapeutic area and geographic area.
  • Market drivers.
  • Market projections through 2022.
  • Competition.
  • Observations and conclusions regarding the future of the botanical and plant-derived drug industry.

Analyst Credentials

Kim Lawson is a graduate of Mount Holyoke College with a degree in English Literature and an M.A. in management from Harvard University's extension program. She acquired experience as a healthcare journalist, including working for John Wiley & Sons as a print reporter, before serving as a research analyst in a small market research firm (in the Research Triangle Park area of North Carolina) that focused on pharmaceuticals and biotechnology. Before joining that firm, she published two reports on emerging and established diagnostics and therapeutics for benign and cancerous breast disease.

Select reports include:

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Note: Reports are discounted or included with certain Memberships. See Membership Options.
 
Published - Aug-2015| Analyst - Kim Lawson| Code - BIO022G

Report Highlights

The global market for botanical and plant-derived drugs was valued at $23.2 billion in 2013 and $24.4 billion in 2014. This total market is expected to reach $25.6 billion in 2015 and nearly $35.4 billion in 2020, with a compound annual growth rate (CAGR) of 6.6% from 2015 to 2020.

Report Includes

  • An overview of the botanical drug industry, with the overall plant-derived drug industry as a backdrop and the global market for these drugs going forward.
  • Analyses of global market trends, with data from 2013 and 2014, estimates for 2015, and projections of CAGRs through 2020.
  • A focus on legal, prescription-required therapeutic medicines sold in the open market; the study does not specifically cover herbals generally sold as dietary supplements (i.e., to promote overall “wellness” rather than to address a specific medical condition or symptoms).
  • Examination of the industry structure, competition, and market drivers.
  • Discussion of market size and segmentation, including breakdowns of sales by therapeutic area and geographic area.
  • Observations and conclusions regarding the future of the botanical and plant-derived drug industry.
Published - Jan-2013| Analyst - Kim Lawson| Code - BIO022F

Report Highlights

The global botanical and plant-derived drug market was valued at $21.4 billion in 2011 and should reach $22.1 billion in 2012. Total market value is expected to reach $26.6 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 3.7%.

Report Includes

  • An overview of the botanical drug industry, with the overall plant-derived drug industry as a backdrop and the global market for these drugs going forward
  • Analyses of global market trends, with data from 2011, estimates for 2012, and projections of compound annual growth rates (CAGRs) through 2017
  • A focus on legal, prescription-required therapeutic medicines sold in the open market; the study does not specifically cover herbals generally sold as dietary supplements (i.e., to promote overall “wellness” rather than to address a specific medical condition or symptoms)
  • Examination of the industry structure, competition, and market drivers
  • Discussion of market size and segmentation, including breakdowns of sales by therapeutic area and geographic area
  • Observations and conclusions regarding the future of the botanical and plant-derived drug industry
  • Comprehensive company profiles of major players.
Published - Feb-2009| Analyst - Kim Lawson| Code - BIO022E

Report Highlights

  • The global market for botanical and plant-derived drugs is expected to increase from $19.5 billion in 2008 to $32.9 billion in 2013, a compound annual growth rate (CAGR) of 11.0%.
  • Botanical drugs generated $127,000.0 in 2008. This segment should reach $2.4 billion in 2013 for a CAGR of 651.7%.
  • All other plant derived drugs generated $19.5 billion in 2008. This is expected to reach $30.5 billion in 2013, for a CAGR of 9.4%.
Published - Jun-2006| Analyst - Andrew McWilliams| Code - BIO022D

Report Highlights

  • The global market for plant-derived drugs was worth an estimated $18 billion in 2005. BCC expects this figure to grow to nearly $19 billion in 2006 and more than $26 billion by 2011, at an AAGR of 6.6% between 2006 and 2011.
  • Cancer treatment is expected to become the largest application of plant-derived drugs by 2011, with 24% of the market.
  • Respiratory problems such as asthma represent the largest medical application of plant-derived drugs in 2005, accounting for 26% of total sales of plant-derived drugs.
  • The North American market (the U.S. and Canada) accounts for over half of the world market for plant-derived drugs, and is projected to increase faster than either the Western European or developed Asian regional markets, exceeding 54% of the global market by 2011

Published - Feb-2003| Analyst - Andrew McWilliams| Code - BIO022C

Report Highlights

  • Total worldwide sales of plant-derived drugs in 2002 are estimated at $13.7 billion.
  • Sales are projected to increase at an average annual growth rate (AAGR) of 6.4% through 2007.
  • The U.S. accounts for 50% of the global plant-derived drug market.
  • The U.S. market will grow faster than foreign markets as a whole, at an AAGR of 7.5% per year vs. 5.3%.

CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
RELATED REPORTS
Share This Report